Nasal  ||| S:0 E:6 ||| JJ
allergies  ||| S:6 E:16 ||| NNS
in  ||| S:16 E:19 ||| IN
the  ||| S:19 E:23 ||| DT
Asian-Pacific  ||| S:23 E:37 ||| JJ
population ||| S:37 E:47 ||| NN
:  ||| S:47 E:49 ||| :
results  ||| S:49 E:57 ||| NNS
from  ||| S:57 E:62 ||| IN
the  ||| S:62 E:66 ||| DT
Allergies  ||| S:66 E:76 ||| NNP
in  ||| S:76 E:79 ||| IN
Asia-Pacific  ||| S:79 E:92 ||| NNP
Survey  ||| S:92 E:99 ||| NNP
The  ||| S:99 E:103 ||| NNP
Allergies  ||| S:103 E:113 ||| NNP
in  ||| S:113 E:116 ||| IN
Asia-Pacific  ||| S:116 E:129 ||| NNP
Survey  ||| S:129 E:136 ||| NNP
describes  ||| S:136 E:146 ||| VBZ
the  ||| S:146 E:150 ||| DT
symptoms ||| S:150 E:158 ||| NNS
,  ||| S:158 E:160 ||| ,
impact ||| S:160 E:166 ||| NN
,  ||| S:166 E:168 ||| ,
and  ||| S:168 E:172 ||| CC
treatment  ||| S:172 E:182 ||| NN
of  ||| S:182 E:185 ||| IN
allergic  ||| S:185 E:194 ||| JJ
rhinitis  ||| S:194 E:203 ||| NNS
( ||| S:203 E:204 ||| -LRB-
AR ||| S:204 E:206 ||| NNP
)  ||| S:206 E:208 ||| -RRB-
across  ||| S:208 E:215 ||| IN
Australia ||| S:215 E:224 ||| NNP
,  ||| S:224 E:226 ||| ,
China ||| S:226 E:231 ||| NNP
,  ||| S:231 E:233 ||| ,
Hong  ||| S:233 E:238 ||| NNP
Kong ||| S:238 E:242 ||| NNP
,  ||| S:242 E:244 ||| ,
Malaysia ||| S:244 E:252 ||| NNP
,  ||| S:252 E:254 ||| ,
Singapore ||| S:254 E:263 ||| NNP
,  ||| S:263 E:265 ||| ,
Taiwan ||| S:265 E:271 ||| NNP
,  ||| S:271 E:273 ||| ,
Vietnam ||| S:273 E:280 ||| NNP
,  ||| S:280 E:282 ||| ,
and  ||| S:282 E:286 ||| CC
the  ||| S:286 E:290 ||| DT
Philippines ||| S:290 E:301 ||| NNPS
.  ||| S:301 E:303 ||| .
The  ||| S:303 E:307 ||| DT
Allergies  ||| S:307 E:317 ||| NNP
in  ||| S:317 E:320 ||| IN
Asia-Pacific  ||| S:320 E:333 ||| NNP
Survey  ||| S:333 E:340 ||| NNP
was  ||| S:340 E:344 ||| VBD
undertaken  ||| S:344 E:355 ||| VBN
to  ||| S:355 E:358 ||| TO
further  ||| S:358 E:366 ||| RB
clarify  ||| S:366 E:374 ||| VB
the  ||| S:374 E:378 ||| DT
prevalence  ||| S:378 E:389 ||| NN
of  ||| S:389 E:392 ||| IN
physician-diagnosed  ||| S:392 E:412 ||| JJ
nasal  ||| S:412 E:418 ||| JJ
allergies  ||| S:418 E:428 ||| NNS
( ||| S:428 E:429 ||| -LRB-
NAs ||| S:429 E:432 ||| NNP
) ||| S:432 E:433 ||| -RRB-
,  ||| S:433 E:435 ||| ,
impact  ||| S:435 E:442 ||| NN
on  ||| S:442 E:445 ||| IN
quality-of-life  ||| S:445 E:461 ||| NNP
( ||| S:461 E:462 ||| -LRB-
QOL ||| S:462 E:465 ||| NNP
) ||| S:465 E:466 ||| -RRB-
,  ||| S:466 E:468 ||| ,
existing  ||| S:468 E:477 ||| VBG
treatment  ||| S:477 E:487 ||| NN
paradigms  ||| S:487 E:497 ||| NNS
and  ||| S:497 E:501 ||| CC
gaps ||| S:501 E:505 ||| NN
,  ||| S:505 E:507 ||| ,
and  ||| S:507 E:511 ||| CC
NA  ||| S:511 E:514 ||| NNP
medications  ||| S:514 E:526 ||| VBD
currently  ||| S:526 E:536 ||| RB
used  ||| S:536 E:541 ||| VBN
in  ||| S:541 E:544 ||| IN
treatment ||| S:544 E:553 ||| NN
.  ||| S:553 E:555 ||| .
Thirty-three  ||| S:555 E:568 ||| JJ
thousand  ||| S:568 E:577 ||| CD
three  ||| S:577 E:583 ||| CD
hundred  ||| S:583 E:591 ||| CD
seventy-eight  ||| S:591 E:605 ||| JJ
households  ||| S:605 E:616 ||| NNS
were  ||| S:616 E:621 ||| VBD
screened  ||| S:621 E:630 ||| VBN
for  ||| S:630 E:634 ||| IN
individuals ||| S:634 E:645 ||| NNS
,  ||| S:645 E:647 ||| ,
â‰¥  ||| S:647 E:649 ||| CD
4  ||| S:649 E:651 ||| CD
years  ||| S:651 E:657 ||| NNS
old ||| S:657 E:660 ||| JJ
,  ||| S:660 E:662 ||| ,
with  ||| S:662 E:667 ||| IN
a  ||| S:667 E:669 ||| DT
physician  ||| S:669 E:679 ||| NN
diagnosis  ||| S:679 E:689 ||| NN
of  ||| S:689 E:692 ||| IN
AR  ||| S:692 E:695 ||| NNP
or  ||| S:695 E:698 ||| CC
NA  ||| S:698 E:701 ||| NNP
and  ||| S:701 E:705 ||| CC
either  ||| S:705 E:712 ||| DT
symptoms  ||| S:712 E:721 ||| NNS
or  ||| S:721 E:724 ||| CC
treatment  ||| S:724 E:734 ||| NN
in  ||| S:734 E:737 ||| IN
the  ||| S:737 E:741 ||| DT
past  ||| S:741 E:746 ||| JJ
12  ||| S:746 E:749 ||| CD
months ||| S:749 E:755 ||| NNS
.  ||| S:755 E:757 ||| .
Standardized  ||| S:757 E:770 ||| JJ
questionnaires  ||| S:770 E:785 ||| NN
were  ||| S:785 E:790 ||| VBD
used  ||| S:790 E:795 ||| VBN
to  ||| S:795 E:798 ||| TO
make  ||| S:798 E:803 ||| VB
comparisons  ||| S:803 E:815 ||| NNS
across  ||| S:815 E:822 ||| IN
regions ||| S:822 E:829 ||| NNS
.  ||| S:829 E:831 ||| .
A  ||| S:831 E:833 ||| DT
total  ||| S:833 E:839 ||| NN
of  ||| S:839 E:842 ||| IN
1043  ||| S:842 E:847 ||| CD
adults  ||| S:847 E:854 ||| NNS
and  ||| S:854 E:858 ||| CC
192  ||| S:858 E:862 ||| CD
children  ||| S:862 E:871 ||| NNS
were  ||| S:871 E:876 ||| VBD
included  ||| S:876 E:885 ||| VBN
in  ||| S:885 E:888 ||| IN
the  ||| S:888 E:892 ||| DT
survey ||| S:892 E:898 ||| NN
.  ||| S:898 E:900 ||| .
Nine  ||| S:900 E:905 ||| CD
percent  ||| S:905 E:913 ||| NN
of  ||| S:913 E:916 ||| IN
participants  ||| S:916 E:929 ||| NNS
were  ||| S:929 E:934 ||| VBD
diagnosed  ||| S:934 E:944 ||| VBN
with  ||| S:944 E:949 ||| IN
AR  ||| S:949 E:952 ||| NNP
with  ||| S:952 E:957 ||| IN
two  ||| S:957 E:961 ||| CD
of  ||| S:961 E:964 ||| IN
three  ||| S:964 E:970 ||| CD
responding  ||| S:970 E:981 ||| NN
that  ||| S:981 E:986 ||| IN
their  ||| S:986 E:992 ||| PRP$
NAs  ||| S:992 E:996 ||| NN
were  ||| S:996 E:1001 ||| VBD
seasonal  ||| S:1001 E:1010 ||| JJ
in  ||| S:1010 E:1013 ||| IN
nature ||| S:1013 E:1019 ||| NN
.  ||| S:1019 E:1021 ||| .
Nasal  ||| S:1021 E:1027 ||| JJ
congestion  ||| S:1027 E:1038 ||| NN
was  ||| S:1038 E:1042 ||| VBD
the  ||| S:1042 E:1046 ||| DT
most  ||| S:1046 E:1051 ||| RBS
common  ||| S:1051 E:1058 ||| JJ
and  ||| S:1058 E:1062 ||| CC
bothersome  ||| S:1062 E:1073 ||| JJ
symptom  ||| S:1073 E:1081 ||| NN
of  ||| S:1081 E:1084 ||| IN
AR ||| S:1084 E:1086 ||| NNP
.  ||| S:1086 E:1088 ||| .
Most  ||| S:1088 E:1093 ||| JJS
participants  ||| S:1093 E:1106 ||| NNS
reported  ||| S:1106 E:1115 ||| VBD
that  ||| S:1115 E:1120 ||| IN
AR  ||| S:1120 E:1123 ||| NNP
impacted  ||| S:1123 E:1132 ||| VBD
their  ||| S:1132 E:1138 ||| PRP$
QOL  ||| S:1138 E:1142 ||| NN
with  ||| S:1142 E:1147 ||| IN
nearly  ||| S:1147 E:1154 ||| RB
one-half  ||| S:1154 E:1163 ||| JJ
citing  ||| S:1163 E:1170 ||| VBG
impairments  ||| S:1170 E:1182 ||| NN
in  ||| S:1182 E:1185 ||| IN
school ||| S:1185 E:1191 ||| NN
/ ||| S:1191 E:1192 ||| CD
work  ||| S:1192 E:1197 ||| NN
performance ||| S:1197 E:1208 ||| NN
/ ||| S:1208 E:1209 ||| CD
productivity ||| S:1209 E:1221 ||| NN
.  ||| S:1221 E:1223 ||| .
Sleep  ||| S:1223 E:1229 ||| JJ
disturbances ||| S:1229 E:1241 ||| NNS
,  ||| S:1241 E:1243 ||| ,
secondary  ||| S:1243 E:1253 ||| JJ
to  ||| S:1253 E:1256 ||| TO
AR ||| S:1256 E:1258 ||| NNP
,  ||| S:1258 E:1260 ||| ,
were  ||| S:1260 E:1265 ||| VBD
also  ||| S:1265 E:1270 ||| RB
shown  ||| S:1270 E:1276 ||| VBN
to  ||| S:1276 E:1279 ||| TO
be  ||| S:1279 E:1282 ||| VB
appreciable ||| S:1282 E:1293 ||| JJ
.  ||| S:1293 E:1295 ||| .
Two-thirds  ||| S:1295 E:1306 ||| NNS
of  ||| S:1306 E:1309 ||| IN
patients  ||| S:1309 E:1318 ||| NNS
took  ||| S:1318 E:1323 ||| VBD
medication  ||| S:1323 E:1334 ||| NN
for  ||| S:1334 E:1338 ||| IN
their  ||| S:1338 E:1344 ||| PRP$
AR ||| S:1344 E:1346 ||| NNP
.  ||| S:1346 E:1348 ||| .
Less  ||| S:1348 E:1353 ||| RBR
than  ||| S:1353 E:1358 ||| IN
one-quarter  ||| S:1358 E:1370 ||| NN
of  ||| S:1370 E:1373 ||| IN
survey  ||| S:1373 E:1380 ||| NN
respondents  ||| S:1380 E:1392 ||| NNS
reported  ||| S:1392 E:1401 ||| VBD
taking  ||| S:1401 E:1408 ||| VBG
an  ||| S:1408 E:1411 ||| DT
intranasal  ||| S:1411 E:1422 ||| JJ
corticosteroid  ||| S:1422 E:1437 ||| NN
and  ||| S:1437 E:1441 ||| CC
the  ||| S:1441 E:1445 ||| DT
satisfaction  ||| S:1445 E:1458 ||| NN
rate  ||| S:1458 E:1463 ||| NN
was  ||| S:1463 E:1467 ||| VBD
similar  ||| S:1467 E:1475 ||| JJ
to  ||| S:1475 E:1478 ||| TO
that  ||| S:1478 E:1483 ||| DT
of  ||| S:1483 E:1486 ||| IN
over-the-counter  ||| S:1486 E:1503 ||| JJ
medications ||| S:1503 E:1514 ||| NN
.  ||| S:1514 E:1516 ||| .
The  ||| S:1516 E:1520 ||| DT
most  ||| S:1520 E:1525 ||| RBS
common  ||| S:1525 E:1532 ||| JJ
reasons  ||| S:1532 E:1540 ||| NNS
cited  ||| S:1540 E:1546 ||| VBD
for  ||| S:1546 E:1550 ||| IN
dissatisfaction  ||| S:1550 E:1566 ||| NN
were  ||| S:1566 E:1571 ||| VBD
related  ||| S:1571 E:1579 ||| VBN
to  ||| S:1579 E:1582 ||| TO
inadequate  ||| S:1582 E:1593 ||| JJ
efficacy  ||| S:1593 E:1602 ||| NN
and  ||| S:1602 E:1606 ||| CC
bothersome  ||| S:1606 E:1617 ||| JJ
side  ||| S:1617 E:1622 ||| NN
effects ||| S:1622 E:1629 ||| NNS
.  ||| S:1629 E:1631 ||| .
AR  ||| S:1631 E:1634 ||| NNP
appears  ||| S:1634 E:1642 ||| VBZ
to  ||| S:1642 E:1645 ||| TO
be  ||| S:1645 E:1648 ||| VB
extremely  ||| S:1648 E:1658 ||| RB
common  ||| S:1658 E:1665 ||| JJ
across  ||| S:1665 E:1672 ||| IN
Asia-Pacific  ||| S:1672 E:1685 ||| JJ
nations ||| S:1685 E:1692 ||| NNS
.  ||| S:1692 E:1694 ||| .
Many  ||| S:1694 E:1699 ||| JJ
individuals  ||| S:1699 E:1711 ||| NNS
with  ||| S:1711 E:1716 ||| IN
AR  ||| S:1716 E:1719 ||| NNP
suffer  ||| S:1719 E:1726 ||| VBP
from  ||| S:1726 E:1731 ||| IN
symptoms  ||| S:1731 E:1740 ||| NNS
that  ||| S:1740 E:1745 ||| WDT
reduce  ||| S:1745 E:1752 ||| VBP
QOL  ||| S:1752 E:1756 ||| NNP
and  ||| S:1756 E:1760 ||| CC
treatment  ||| S:1760 E:1770 ||| NN
gaps  ||| S:1770 E:1775 ||| NNS
exist  ||| S:1775 E:1781 ||| VBP
with  ||| S:1781 E:1786 ||| IN
current  ||| S:1786 E:1794 ||| JJ
therapies ||| S:1794 E:1803 ||| NNS
.  ||| S:1803 E:1805 ||| .
Through  ||| S:1805 E:1813 ||| IN
identification  ||| S:1813 E:1828 ||| NN
of  ||| S:1828 E:1831 ||| IN
disease  ||| S:1831 E:1839 ||| NN
impact  ||| S:1839 E:1846 ||| NN
and  ||| S:1846 E:1850 ||| CC
highlighting  ||| S:1850 E:1863 ||| JJ
treatment  ||| S:1863 E:1873 ||| NN
gaps ||| S:1873 E:1877 ||| NN
,  ||| S:1877 E:1879 ||| ,
clinicians  ||| S:1879 E:1890 ||| NNS
may  ||| S:1890 E:1894 ||| MD
better  ||| S:1894 E:1901 ||| RB
understand  ||| S:1901 E:1912 ||| VB
and  ||| S:1912 E:1916 ||| CC
treat  ||| S:1916 E:1922 ||| VB
AR ||| S:1922 E:1924 ||| NNP
,  ||| S:1924 E:1926 ||| ,
leading  ||| S:1926 E:1934 ||| VBG
to  ||| S:1934 E:1937 ||| TO
improvements  ||| S:1937 E:1950 ||| NNS
in  ||| S:1950 E:1953 ||| IN
overall  ||| S:1953 E:1961 ||| JJ
patient  ||| S:1961 E:1969 ||| NN
satisfaction  ||| S:1969 E:1982 ||| NN
and  ||| S:1982 E:1986 ||| CC
QOL ||| S:1986 E:1989 ||| NNP
.  ||| S:1989 E:1991 ||| .
